Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of Stock

Key Points

• United Therapeutics EVP Paul Mahon sold 8,300 shares at an average price of $482.03, generating approximately $4.0 million. His remaining stake declined by 15.52% to 45,172 shares.
• UTHR shares fell 0.4% to $490.24, with the stock trading below its 50-day and 200-day moving averages. The company has a $21.03 billion market capitalization and a 12-month range of $375.61 to $609.35.
• United Therapeutics beat quarterly EPS expectations ($7.27 versus $6.86), although revenue declined 1.9% year over year. Analysts maintain a Moderate Buy consensus rating with an average price target of $646, while institutional investors own 94.08% of the stock.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the company's stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $482.03, for a total transaction of $4,000,849.00. Following the completion of the transaction, the executive vice president owned 45,172 shares in the company, valued at approximately $21,774,259.16. The trade was a 15.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Trading Down 0.4%

NASDAQ:UTHR traded down $1.78 on Thursday, reaching $490.24. 469,574 shares of the stock traded hands, compared to its average volume of 494,247. The company has a market capitalization of $21.03 billion, a price-to-earnings ratio of 17.54, a PEG ratio of 2.56 and a beta of 0.56. United Therapeutics Corporation has a 12 month low of $375.61 and a 12 month high of $609.35. The company's fifty day simple moving average is $528.12 and its 200 day simple moving average is $539.79.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the prior year, the firm posted $6.41 earnings per share. The business's revenue was down 1.9% on a year-over-year basis. Equities analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Arjuna Capital raised its position in shares of United Therapeutics by 2.8% in the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock valued at $393,000 after buying an additional 18 shares during the last quarter. Sage Rhino Capital LLC boosted its position in United Therapeutics by 5.1% during the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock worth $281,000 after acquiring an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC grew its stake in United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock valued at $276,000 after acquiring an additional 24 shares in the last quarter. Meeder Advisory Services Inc. grew its stake in United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock valued at $392,000 after acquiring an additional 26 shares in the last quarter. Finally, Independent Advisor Alliance raised its holdings in United Therapeutics by 3.3% in the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company's stock valued at $406,000 after acquiring an additional 27 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on UTHR shares. TD Cowen reaffirmed a "buy" rating on shares of United Therapeutics in a research report on Thursday, May 21st. Bank of America reduced their target price on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a report on Friday, July 10th. Weiss Ratings cut United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research note on Thursday, August 27th. Royal Bank Of Canada lowered their price target on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Finally, Morgan Stanley set a $515.00 price objective on United Therapeutics in a research report on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $646.00.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source